Clinical Trial Update: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 study of HB-201 in newly diagnosed HPV16-positive oropharyngeal cancer and locally advanced cervical cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-16 Positive Cervical Cancer
• Hpv-16 Positive Oropharyngeal Cancer

Drugs mentioned

• HB-201

Snippet

Sponsor: Hookipa Biotech GmbH | Conditions: HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer | EARLY_Phase 1 | Status: TERMINATED